Buy Galvus (Vildagliptin) anti-diabetic medication
Cheap qualitative Vildagliptin 50 mg tablets online
HOW AND WHERE TO BUY VILDAGLIPTIN (GALVUS) 50 MG TABLETS OR CAPSULES ONLINE:
GALVUS (VILDAGLIPTIN): WARNINGS AND PRECAUTIONS
Galvus (Vildagliptin) is not a substitute for insulin in insulin-requiring patients. Galvus should not be used in patients with type 1 diabetes or for the treatment of diabetic ketoacidosis.
There is limited experience in patients with ESRD on haemodialysis. Therefore Galvus should be used with caution in these patients.
Vildagliptin (Galvus) should not be used in patients with hepatic impairment, including patients with pre-treatment ALT or AST > 3x ULN.
Liver enzyme monitoring
Rare cases of hepatic dysfunction (including hepatitis) have been reported. In these cases, the patients were generally asymptomatic without clinical sequelae and liver function test results returned to normal after discontinuation of treatment. Liver function tests should be performed prior to the initiation of treatment with Galvus in order to know the patient's baseline value. Liver function should be monitored during treatment with Galvus at three-month intervals during the first year and periodically thereafter. Patients who develop increased transaminase levels should be monitored with a second liver function evaluation to confirm the finding and be followed thereafter with frequent liver function tests until the abnormality(ies) return(s) to normal. Should an increase in AST or ALT of 3x ULN or greater persist, withdrawal of Galvus therapy is recommended.
Patients who develop jaundice or other signs suggestive of liver dysfunction should discontinue Galvus (Vildagliptin).
Following withdrawal of treatment with Galvus and LFT normalisation, treatment with Vildagliptin (Galvus) should not be reinitiated.
A clinical trial of vildagliptin in patients with New York Heart Association (NYHA) functional class I-III showed that treatment with vildagliptin was not associated with a change in left-ventricular function or worsening of pre-existing congestive heart failure (CHF) versus placebo. Clinical experience in patients with NYHA functional class III treated with vildagliptin is still limited and results are inconclusive.
There is no experience of vildagliptin use in clinical trials in patients with NYHA functional class IV and therefore use is not recommended in these patients.
Skin lesions, including blistering and ulceration have been reported in extremities of monkeys in non-clinical toxicology studies (see section 5.3). Although skin lesions were not observed at an increased incidence in clinical trials, there was limited experience in patients with diabetic skin complications. Furthermore, there have been post-marketing reports of bullous and exfoliative skin lesions.
Therefore, in keeping with routine care of the diabetic patient, monitoring for skin disorders, such as blistering or ulceration, is recommended.
Use of vildagliptin has been associated with arisk of developing acute pancreatitis. Patients should be informed of the characteristic symptom of acute pancreatitis.
If pancreatitis is suspected, vildagliptin should be discontinued; if acute pancreatitis is confirmed, vildagliptin should not be restarted. Caution should be exercised in patients with a history of acute pancreatitis.
Sulphonylureas are known to cause hypoglycaemia. Patients receiving vildagliptin in combination with a sulphonylurea may be at risk for hypoglycaemia. Therefore, a lower dose of sulphonylurea may be considered to reduce the risk of hypoglycaemia.
The tablets contain lactose. Patients with rare hereditary problems of galactose intolerance, the Lapp lactase deficiency or glucose-galactose malabsorption should not take this medicinal product.
Galvus related pharmaceutical drugs and medications
|Trade name of the drug
||Pharmaceutical forms and doses
|Januvia warnings and precautions - Sitagliptin Phosphate
||Tablets; Oral; Sitagliptin Phosphate 100 mgTablets; Oral; Sitagliptin Phosphate 25 mg
|Janumet warnings and precautions - Sitagliptin Phosphate
||Tablets, Film-Coated; Oral; Metformin Hydrochloride 1 g; Sitagliptin Phosphate 50 mgTablets, Film-Coated; Oral; Metformin Hydrochloride 850 mg; Sitagliptin Phosphate 50 mg
|Lantus warnings and precautions - Insulin Glargine
||Injectable; Injection; Insulin Glargine recombinant 100 IU / ml
||Sanofi-AventisFour StarZuellig Pharma
Buy Galvus (Vildagliptin) Online
Galvus prescribing information
Copyright © Buy Vildagliptin Online